Sequoia Financial Advisors LLC Buys Shares of 4,265 Celcuity, Inc. $CELC

Sequoia Financial Advisors LLC purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, Holdings Channel reports. The firm purchased 4,265 shares of the company’s stock, valued at approximately $425,000.

Several other large investors have also modified their holdings of CELC. Creative Planning acquired a new stake in shares of Celcuity in the second quarter valued at approximately $177,000. Rhumbline Advisers grew its position in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Celcuity in the second quarter valued at approximately $169,000. Quantinno Capital Management LP grew its position in shares of Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares during the last quarter. Finally, Paloma Partners Management Co grew its position in shares of Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is owned by company insiders.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity announced amendments to its Phase 3 VIKTORIA-2 trial for gedatolisib, expanding the study to include endocrine-sensitive patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The broader trial population could increase the drug’s commercial opportunity if results remain positive. Article Title
• Positive Sentiment: Needham & Company reiterated its Buy rating on Celcuity and raised its price target to $157, signaling continued analyst confidence in the company’s pipeline and upside potential. Article Title
• Positive Sentiment: Celcuity reported first-quarter 2026 earnings of ($0.97) per share, beating consensus estimates of ($1.07). While the company is still unprofitable, the smaller-than-expected loss likely supported investor sentiment. Article Title
• Neutral Sentiment: Celcuity also provided its first-quarter financial results and a corporate update, but the main market focus appears to be on the trial expansion and analyst upgrades rather than the broader financial details. Article Title
• Neutral Sentiment: An earnings call transcript was published for the quarter, which may help investors assess management’s commentary on trial progress, cash needs, and commercialization plans. Article Title

Analyst Ratings Changes

CELC has been the topic of several research reports. Citizens Jmp increased their price target on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday, May 4th. Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a research report on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Monday, April 20th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research report on Monday, May 4th. Finally, Craig Hallum reiterated a “buy” rating and issued a $189.00 price target on shares of Celcuity in a research report on Monday, May 4th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $140.20.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $137.68 on Monday. Celcuity, Inc. has a 1 year low of $10.26 and a 1 year high of $151.02. The firm’s 50 day moving average price is $118.86 and its 200 day moving average price is $106.94. The firm has a market cap of $6.71 billion, a P/E ratio of -35.30 and a beta of 0.09. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -3.87 earnings per share for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.